Neurofilament light chain and MRI volume parameters as markers of neurodegeneration in multiple sclerosis

被引:2
|
作者
Filippi, Pavol [1 ]
Vestenicka, Veronika [1 ]
Siarnik, Pavel [1 ]
Sivakova, Monika [1 ]
Copikova-Cudrakova, Daniela [1 ]
Belan, Vit'azoslav [2 ]
Hanes, Jozef [3 ]
Novak, Michal [3 ]
Kollar, Branislav [1 ]
Turcani, Peter [1 ]
机构
[1] Comenius Univ, Fac Med, Dept Neurol 1, Mickiewiczova 13, Bratislava 81369, Slovakia
[2] Dr Magnet Kramare, Bratislava, Slovakia
[3] Slovak Acad Sci, Inst Neuroimmunol, Bratislava, Slovakia
关键词
Multiple Sclerosis; Neurofilament Light Chain; Neurodegeneration; Single-molecule Array (SIMOA (R)); Magnetic Resonance Imaging; MRI Volume Parameters; Icobrain; Biomarker; BRAIN ATROPHY; SERUM NEUROFILAMENT; DISABILITY PROGRESSION; DISEASE-ACTIVITY; MATTER; QUANTIFICATION; RELEVANCE; LESIONS; DAMAGE; MS;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Neurofilament light chain (NfL) is considered a major marker of neurodegeneration and disease activity. Higher levels of NfL are associated with worse clinical outcomes and increased brain atrophy. In treated patients with Relapsing-Remitting Multiple Sclerosis (RRMS), we aimed to determine the level of NfL, an association between NfL and demographic, clinical and magnetic resonance imaging (MRI) characteristics as well as brain volume parameters. We wanted to confirm that level of NfL is clinically useful as biomarker of neurodegeneration and disease activity. METHODS: 56 treated RRMS patients were enrolled. Plasmatic levels of NfL (pNfL) were measured by SIMOA (R) technique. Clinical severity of MS was expressed by Expanded Disability Status Scale (EDSS), and volumetric analysis of MRI data was performed using Icobrain software. RESULTS: The mean pNfL level was significantly higher in MS patients than in healthy controls (14.73 +/- 6.38 versus 6.67 +/- 3.9, p<0.001). In patients, we did not find association between pNfL and MRI activity, number of new T2 lesions, and number of enhancing lesions. Levels of pNfL correlated significantly with atrophy of whole brain volume (Wbv), atrophy of grey matter volume (Gmv), and negatively with Wbv. We found significantly positive correlation between pNfL levels and EDSS. CONCLUSION: Study shows association of pNfL with Wbv, presence of brain atrophy and EDSS, and strong correlation of EDSS with multiple MRI volume parameters. We did not confirm association pNfL with disease activity. Our data suggest that pNfL and MRI volume parameters could be considered as biomarkers of neurodegeneration in MS.
引用
收藏
页码:17 / 26
页数:10
相关论文
共 50 条
  • [31] Demographic and disease-related factors impact on cerebrospinal fluid neurofilament light chain levels in multiple sclerosis
    Revendova, Kamila Zondra
    Cucuzza, Chiara Starvaggi
    Manouchehrinia, Ali
    Khademi, Mohsen
    Bar, Michal
    Leppert, David
    Sandberg, Elisabeth
    Ouellette, Russell
    Granberg, Tobias
    Piehl, Fredrik
    BRAIN AND BEHAVIOR, 2023, 13 (01):
  • [32] MRI Lesion State Modulates the Relationship Between Serum Neurofilament Light and Age in Multiple Sclerosis
    Rosso, Mattia
    Healy, Brian C.
    Saxena, Shrishti
    Paul, Anu
    Bjornevik, Kjetil
    Kuhle, Jens
    Benkert, Pascal
    Leppert, David
    Guttmann, Charles
    Bakshi, Rohit
    Weiner, Howard L.
    Chitnis, Tanuja
    JOURNAL OF NEUROIMAGING, 2021, 31 (02) : 388 - 393
  • [33] Implications of extreme serum neurofilament light chain levels for the management of patients with relapsing multiple sclerosis
    Engel, Sinah
    Protopapa, Maria
    Steffen, Falk
    Papanastasiou, Vakis
    Nicolaou, Christoforos
    Protopapas, Michalis
    Zipp, Frauke
    Bittner, Stefan
    Luessi, Felix
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [34] Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management
    Freedman, Mark S.
    Gnanapavan, Sharmilee
    Booth, Ronald A.
    Calabresi, Peter A.
    Khalil, Michael
    Kuhle, Jens
    Lycke, Jan
    Olsson, Tomas
    EBIOMEDICINE, 2024, 101
  • [35] Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis
    Lorenzo Gaetani
    Nicola Salvadori
    Viviana Lisetti
    Paolo Eusebi
    Andrea Mancini
    Lucia Gentili
    Angela Borrelli
    Emilio Portaccio
    Paola Sarchielli
    Kaj Blennow
    Henrik Zetterberg
    Lucilla Parnetti
    Paolo Calabresi
    Massimiliano Di Filippo
    Journal of Neurology, 2019, 266 : 2157 - 2163
  • [36] Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis
    Gaetani, Lorenzo
    Salvadori, Nicola
    Lisetti, Viviana
    Eusebi, Paolo
    Mancini, Andrea
    Gentili, Lucia
    Borrelli, Angela
    Portaccio, Emilio
    Sarchielli, Paola
    Blennow, Kaj
    Zetterberg, Henrik
    Parnetti, Lucilla
    Calabresi, Paolo
    Di Filippo, Massimiliano
    JOURNAL OF NEUROLOGY, 2019, 266 (09) : 2157 - 2163
  • [37] Disease biomarkers in multiple sclerosis: current serum neurofilament light chain perspectives
    Jakimovski, Dejan
    Dwyer, Michael G.
    Bergsland, Niels
    Weinstock-Guttman, Bianca
    Zivadinov, Robert
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (04) : 329 - 340
  • [38] Neurofilament light chain as an indicator of exacerbation prior to clinical symptoms in multiple sclerosis
    Edwards, Keith R.
    Garten, Lore
    Button, Judy
    O'Connor, Judy
    Kamath, Vineetha
    Frazier, Carol
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 31 : 59 - 61
  • [39] Multidimensional overview of neurofilament light chain contribution to comprehensively understanding multiple sclerosis
    Kolliker Frers, Rodolfo A.
    Otero-Losada, Matilde
    Kobiec, Tamara
    Udovin, Lucas D.
    Aon Bertolino, Maria Laura
    Herrera, Maria, I
    Capani, Francisco
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [40] Neurofilament Light Chain and Multiple Sclerosis: Building a Neurofoundational Model of Biomarkers and Diagnosis
    Aburashed, Rany
    Eghzawi, Ansam
    Long, Daniel
    Pace, Robert
    Madha, Ali
    Cote, Jeanie
    NEUROLOGY INTERNATIONAL, 2025, 17 (04):